Meningeal Lymphatics Platform

Our programs
Phase 1
Phase 2
Phase 3
Meningeal Lymphatics Platform

A platform that aims to correct lymphatic dysfunction in the brain to potentially improve outcomes for a range of neurodegenerative and neuroinflammatory conditions that are not currently effectively treated, such as Alzheimer’s disease and Parkinson’s disease.

Phase completedPhase in progressRegistration-enabling studies planned
Altering lymphatic flow, both in the CNS and other parts of the body

The lymphatic system is an important part of the immune system, gastrointestinal system and central nervous system (CNS). Loss of lymphatic flow can play a critical role in diseases of these systems. One of PureTech's academic collaborators discovered a functional lymphatic system in the meninges of the brain that forms the basis of its meningeal lymphatics discovery research program for treating neurodegenerative diseases.

  • Innovative Approach for Solving the Problem
    • The meningeal lymphatics have been described as the “brain drain,” a route through which macromolecules are flushed from the brain in cerebrospinal fluid. Among the macromolecules that are drained via the lymphatics are pathogenic macromolecules such as amyloid-beta and tau, which are both associated with Alzheimer’s disease (AD) pathology, as well as alpha-synuclein, which is associated with Parkinson’s disease. Blocking the lymphatic flow increases levels of these molecules in the brain. In animal models of AD, AD-associated tauopathies and Parkinson’s disease, blockade of meningeal lymphatic flow significantly exacerbated disease progression and severity and improving flow through aged meningeal lymphatics improved cognitive brain function in these animal models. With aging, the lymphatic vessels that drain the brain become dysfunctional and no longer drain as efficiently.
    • The “lymphedematous characteristics” of meningeal lymphatic vessels in aged animals might be leading to inefficient clearance of pathologic macromolecules and potentially increase risk for neurodegenerative diseases. Restoration of lymphatic flow may then be a novel class of therapies for neurodegeneration, and PureTech believes that augmenting meningeal lymphatic vasculature function may potentially improve outcomes for a range of neurodegenerative and neuroinflammatory conditions that are not currently effectively treated.
  • Intellectual Property
    • PureTech has broad intellectual property coverage around its meningeal lymphatics discovery research program, which includes exclusively licensed patent applications covering compositions of matter, methods of use and methods of treatment encompassing its platform-based brain lymphatic technologies, including the identification of macromolecular targets, as well as various classes of brain lymphatic targeting therapeutics for use in the treatment of a wide range of neurodegenerative and neuroinflammatory conditions, as well as various neuropathies and cancers.
    • As of June 30, 2020, PureTech's meningeal lymphatics discovery research program patent portfolio consists of eight patent families comprising eight U.S. patent applications, two international PCT applications and five foreign patent applications exclusively licensed from the University of Virginia Licensing & Ventures Group, and one family of one U.S. application exclusively owned by PureTech. Any patents to issue from the in-licensed patent applications are expected to expire in 2037 through 2041, exclusive of possible patent term adjustments or extensions or other forms of exclusivity.
  • Expected Milestones
    • PureTech is exploring multiple ways of altering lymphatic flow, both in the CNS and other parts of the body. Starting with LYT-100, PureTech will continue to develop novel therapeutic candidates that target inflammation, fibrosis and other mechanisms that impair lymphatic flow. PureTech also has ongoing discovery efforts to explore new mechanisms with the goal to advance, in-license and/or acquire assets that it can develop for diseases of lymphatic flow.
    • PureTech also intends to explore the application of other potential new product candidates from its meningeal lymphatics platform for a range of neurodegenerative diseases.